LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).
… Alberta. They will review topics related to the extension trial data, as well as key takeaways in relation to the … residency training at the University of Ottawa and Clinical Genetics fellowship training at the University of … production of functional CEP290 protein. In a Phase 1/2 clinicaltrial sepofarsen reported rapid, significant and …
… Conference and provides an update on the ongoing Phase 1b trial Key Updates An oral presentation on the final results … today announced presentation of data from two clinical studies of QR-010 in oral and poster sessions at the … session “New therapies targeting CFTR: what's new from the clinical trials pipeline?” from 15:00 – 16:30 central …
ProQR receives exclusive worldwide license for IONIS-RHO-2.5Rx, now QR-1123, for autosomal dominant retinitis pigmentosa (adRP), a rare inherited form of blindness with no approved therapy